Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

Kernan, Walter N., Viscoli, Catherine M., Furie, Karen L., Young, Lawrence H., Inzucchi, Silvio E., Gorman, Mark, Guarino, Peter D., Lovejoy, Anne M. +19 more·2016·New England Journal of Medicine
DOI 10.1056/nejmoa1506930

Cited by (1,110)

Items 701–800 of 1,110

  1. Enhanced Outcomes in Type 2 Diabetes Patients With Acute Kidney Disease Through Thiazolidinedione
    Li‐Yang Chang, Hung‐Wei Liao, Jui‐Yi Chen, Vin‐Cent Wu · 2024 · The Journal of Clinical Endocrinology & Metabolism
  2. Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial
    Niki Katsiki, Dimitri P. Mikhailidis · 2016 · Journal of Diabetes and its Complications
  3. Pharmaceutical Interventions for Diabetes Prevention in Patients at Risk
    Sudesna Chatterjee, Melanie Jane Davies, Kamlesh K. Khunti · 2017 · American Journal of Cardiovascular Drugs
  4. Basic Concepts in Insulin Resistance and Diabetes Treatment
    Fernando Bril, Kenneth J. Cusi · 2017 · Springer eBooks
  5. Inhibition of perivascular mast cell activation is involved in the atheroprotective effect of rosiglitazone in apolipoprotein E–deficient mice
    Qinglang Li, Ying Xiao, Guihua Lu · 2019 · Biochemical and Biophysical Research Communications
  6. Peroxisome proliferator‐activated receptor gamma blunts endothelin‐1‐mediated contraction of the uterine artery in a murine model of high‐altitude pregnancy
    Sydney L. Lane, Alexandrea S. Doyle, Elise S. Bales, Julie A. Houck, Ramón A. Lorca, LORNA GRINDLAY MOORE, Colleen Glyde Julian · 2020 · The FASEB Journal
  7. Prediction of Persistent Impaired Glucose Tolerance in Patients with Minor Ischemic Stroke or Transient Ischemic Attack
    Elizabeth Osei, Heleen M. den Hertog, Susanne Fonville, Paul J.A.M. Brouwers, Laus J.M.M. Mulder, Peter J. Koudstaal, Diederik W.J. Dippel, Adrienne A.M. Zandbergen, Hester Floor Lingsma · 2020 · Journal of Stroke and Cerebrovascular Diseases
  8. Association of Longitudinal Glycemia with Diffusion Weighted Imaging Lesions in Spontaneous Intracerebral Hemorrhage
    Rajeev Kumar Garg, Bichun Ouyang, Jawad Khan, Nicholas G. Panos, Ivan Rocha Ferreira da Silva, Deborah Hall, Starane Shepherd, Sayona John, Mehmet Koçak, Sudeep H. Bhabad et al. · 2020 · Journal of Stroke and Cerebrovascular Diseases
  9. Pathophysiology and Management of Dyslipidemias Associated with Insulin-Resistant States
    Kevin Carl Maki, Lane B. Benes, Mary R. Dicklin · 2020 · Contemporary cardiology
  10. Diabetes medications with cardiovascular protection: the likelihood of benefit from combination therapy increases further following new evidence during 2020
    Robert E. J. Ryder, Muhammad A. Abdul-Ghani, Ralph Anthony DeFronzo · 2020 · British Journal of Diabetes
  11. Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies
    Angelo Avogaro, Francesco Barillà, Franco Luigi Cavalot, Agostino Consoli, Massimo Federici, Massimo Mancone, Stefania Paolillo, Roberto Pedrinelli, Gianluca Perseghin, Pasquale Perrone Filardi et al. · 2021 · Nutrition Metabolism and Cardiovascular Diseases
  12. A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease
    Tariq Ahmad, Ralph J. Riello, Silvio E. Inzucchi · 2021 · European Cardiology Review
  13. Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance
    Elizabeth Osei, Adrienne A.M. Zandbergen, Paul J.A.M. Brouwers, Laus J.M.M. Mulder, Peter J. Koudstaal, Hester Floor Lingsma, Diederik W.J. Dippel, Heleen den Hertog · 2021 · BMJ Open
  14. Macrovascular Complications
    Michael McRae, Cecilia C. Low Wang · 2022 · Primary Care Clinics in Office Practice
  15. Pioglitazone
    David Karásek · 2020 · Vnitřní lékařství
  16. Pioglitazone and cardiovascular risk reduction: time for a second look?
    Ana Luisa Perdigoto, Lawrence H. Young, Silvio E. Inzucchi · 2016 · Cardiovascular Endocrinology
  17. Diabetes-Related Dyslipidemia and Cardiovascular Events
    Vivian Andrew Fonseca, Dragana Lovre · 2017 · The American Journal of the Medical Sciences
  18. Antidiabetic drugs for stroke prevention in patients with type-2 diabetes. The neurologist's point of view
    Blanca Fuentes · 2018 · Medicina Clínica (English Edition)
  19. Managing Diabetes by Maintaining Healthier Beta Cells: A Fresh Perspective for Diabetes Educators
    Gary Scheiner, Stanley S. Schwartz, Mary E. Herman · 2018 · AADE in Practice
  20. Recent Perspective on Thiazolidinedione
    Won Jun Kim · 2021 · Journal of Korean Diabetes
  21. Approach to the treatment of diabetes in the elderly
    Yüksel Altuntaş · 2019 · SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital
  22. Preventing recurrent stroke and other serious vascular events
    Cathra Halabi, René A. Colorado, Karl M. Meisel · 2019 · Wiley eBooks
  23. Biomimetic dynamic nanomedicine SrHCF: Lattice self-reconstruction based on Fe2+ response to achieve synergistic “ferrous chelation-antioxidation-calcium antagonism-inflammation inhibition” quadruple treatment of CIRI
    Tingli Xiong, Shuya Wang, Xiaojing Shi, Ruishi Li, Wenxuan Zheng, Weimin Qi, Min Liu, Lin Dai, Qiong Huang, Kelong Ai · 2025 · Bioactive Materials
  24. Insulin resistance in cerebral small vessel disease: a mini review
    Chen Su, Zhigang Cui, Junhong Guo · 2026 · Frontiers in Neuroscience
  25. Silent Myocardial Infarction and Risk of Stroke Recurrence: A Post Hoc Analysis of the IRIS Trial
    Mohamed Ridha, Cenai Zhang, Stephen McCullough, Catherine M. Viscoli, Richa Sharma, Hooman Kamel, Alexander Eliot Merkler · 2025 · Journal of the American Heart Association
  26. Thiazolidinedione Use and Cardiovascular Outcomes in Patients With Type 2 Diabetes Who Underwent Carotid Artery Revascularization
    Jun Hwee Kim, Jimin Jeon, Seok‐Jae Heo, Tae‐Jin Song, Minyoul Baik, Joonsang Yoo, Jun-Hwee Kim · 2025 · Journal of the American Heart Association
  27. Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT study
    Muhammad A Abdul‐Ghani, CURTISS L. PUCKETT, Siham Abdelgani, Aurora Merovci, Olga Lavrynenko, John M. Adams, Curtis L. Triplitt, Ralph A. DeFronzo · 2025 · BMJ Open Diabetes Research & Care
  28. The Role of Diabetes and SGLT2 Inhibitors in Cerebrovascular Diseases
    Bayan Moustafa, Gabriela Trifan · 2025 · Current Neurology and Neuroscience Reports
  29. Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms
    HARPREET SINGH BAJAJ, Bernard Zinman · 2018 · Physiology
  30. Diabetes prevention and cardiovascular complications
    Silvio E. Inzucchi, Catherine M. Viscoli, Lawrence H. Young, Walter N. Kernan · 2019 · Diabetologia
  31. Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?
    Muhammad A Abdul‐Ghani, Ralph Anthony DeFronzo · 2021 · Expert Opinion on Pharmacotherapy
  32. A Systematic Approach to Treating Early Metabolic Disease and Prediabetes
    Nicholas W. Carris, Brian E. Bunnell, Rahul Suresh Mhaskar, Christopher Garnet DuCoin, Marilyn Stern · 2023 · Diabetes Therapy
  33. Pioglitazone and barriers to effective post-stroke comorbidity management in stroke survivors with diabetes
    Hala F. Azhari, Jonathan Hewitt, Alexander Smith, Martin O’Neill, Terence J. Quinn, Jesse Dawson · 2024 · Neurosciences
  34. Clinical pharmacokinetics of leriglitazone and a translational approach using PBPK modeling to guide the selection of the starting dose in children
    Estefania Traver, Laura Rodríguez‐Pascau, Uwe Meya et al. · 2024 · CPT Pharmacometrics & Systems Pharmacology
  35. Orchestra of ligand-activated transcription factors in the molecular symphony of SERPINE 1 / PAI-1 gene regulation
    Aneta Vrzalová, Radim Vrzal · 2024 · Biochimie
  36. Cardiovascular Outcomes With Antidiabetic Drugs in People With Type 2 Diabetes and a Prior Stroke
    Jae Hyun Bae, Jimi Choi, Nam Hoon Kim, Sin Gon Kim · 2025 · Mayo Clinic Proceedings
  37. Diretriz de Síndrome Coronariana Crônica – 2025
    Luı́z Antonio Machado César, Luís Henrique Wolff Gowdak, Ricardo Pavanello, João Fernando Monteiro Ferreira, Bruno Mahler Mioto, Nilson Tavares Poppi, Cledson Jatiniel Lima Mendonça, Adenalva Lima de Souza Beck, Adriana Soares Xavier de Brito, Alexandre Abizaid et al. · 2025 · Arquivos Brasileiros de Cardiologia
  38. The year in cardiology 2017: prevention
    Børge Grønne Nordestgaard, Francesco Cosentino, Ulf Landmesser, Ulrich Laufs · 2017 · European Heart Journal
  39. Long-term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study
    Giovanni Sartore, Nino Cristiano Chilelli, Roberta Seraglia · 2019 · Acta Diabetologica
  40. Targeting multiple domains of residual cardiovascular disease risk in patients with diabetes
    Kershaw V. Patel, Muthiah Vaduganathan · 2020 · Current Opinion in Cardiology
  41. Atheroprotective effects of 17β-oestradiol are mediated by peroxisome proliferator-activated receptor γ in human coronary artery smooth muscle cells
    Julian Jehle, Vedat Tiyerili, Sandra Adler · 2020 · Archives of Medical Science - Atherosclerotic Diseases
  42. Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction Induced Experimentally in Diabetic Rats
    Ahmed Bahriz, Yassmin Ismaiel, Abeer A. Abdelhameed · 2021 · Benha Medical Journal
  43. Trans-endothelial trafficking of metabolic substrates and its importance in cardio-metabolic disease
    Ashton Faulkner · 2021 · Biochemical Society Transactions
  44. Constructing a Smartphone-Controlled Semiautomatic Theranostic System for Glucose Homeostasis in Diabetic Mice
    Guiling Yu, Yuanhuan Yu, Haifeng Ye · 2021 · Methods in molecular biology
  45. Cardioprotective Effects of Pioglitazone in Type 2 Diabetes
    Devjit Tripathy, Carolina Solis‐Herrera, Robert E. J. Ryder · 2021 · Diabetes Spectrum
  46. IMPACT OF ANTIDIABETIC DRUGS ON RISK AND OUTCOME OF COVID-19 INFECTION: A REVIEW
    Adnan A. Zainal, Marwan M. Merkhan · 2022 · Military Medical Science Letters
  47. Position Paper on the Diagnosis and Treatment of Peripheral Arterial Disease (PAD) in People with Diabetes Mellitus
    Bernd M. Balletshofer, Dittmar Böckler, Holger Diener, Jörg Heckenkamp, Wulf D. Ito, Marcos Katoh, Holger Lawall, Nasser M. Malyar, Yves Oberländer, Peter Reimer et al. · 2022 · Experimental and Clinical Endocrinology & Diabetes
  48. Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease
    Hiroaki Yagyu, Hitoshi Shimano · 2022 · Journal of Diabetes Investigation
  49. Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial
    Atsushi Tanaka, Takumi Imai, Michio Shimabukuro, Isao Taguchi, Akira Sezai, Shigeru Toyoda, Hirotaka Watada, Junya Ako, Koichi Node, the CANDLE trial investigators · 2022 · Cardiovascular Diabetology
  50. Reflections on the state of diabetes research and prospects for treatment
    Domenico Accili, Wen Juan Du, Takumi Kitamoto, Taiyi Kuo, Wendy M. McKimpson, Yasutaka Miyachi, Maria Mukhanova, Jinsook Son, Liheng Wang, Hitoshi Watanabe · 2022 · Diabetology International
  51. Ongoing and Future Clinical Trials of Pharmacotherapy for Heart Failure
    Taha Mansoor, Subaina N. Khalid, Muhammad Ibraiz Bilal, Sardar Hassan Ijaz, Marat Fudim, Stephen John Greene, Haider Javed Warraich, Vijay Nambi, Salim S. Virani, Gregg C. Fonarow et al. · 2024 · American Journal of Cardiovascular Drugs
  52. Fluoxetine in stroke (FOCUS) trial—reasons to be cheerful about antidepressants in stroke?
    Terence J. Quinn · 2019 · Annals of Translational Medicine
  53. Pharmacotherapy of Diabetes Focused on Stroke
    Young Sang Lyu, Jin‐Hwa Kim, Sang-Yong Kim · 2019 · Journal of the Korean Neurological Association
  54. Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease of Patients with Diabetes
    Kenneth R. Feingold · 2020 · Europe PMC (PubMed Central)
  55. Thirty-six months recurrence after acute ischemic stroke among patients with comorbid type 2 diabetes: A nested case-control study
    Lu Wang, Hongyun Li, Jiheng Hao, Chao Liu, Jiyue Wang, Jingjun Feng, Zheng Guo, Yulu Zheng, Yanbo Zhang, Hongxiang Li et al. · 2022 · Frontiers in Aging Neuroscience
  56. Insulin and Other Hypoglycemic Drugs
    Jasmine M. Pittman, Laura A. Schalliol, Sidhartha D. Ray · 2017 · Side effects of drugs annual
  57. The shifting paradigm in the treatment of type 2 diabetes mellitus—A cardiologist's perspective
    Saeeda Fatima, Ayesha Jameel, Fnu Ayesha, Dhananjai J. Menzies · 2017 · Clinical Cardiology
  58. Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR)
    Suzanne V. Arnold, Darren K. McGuire, Silvio E. Inzucchi, Fengming Tang, Sanjeev N. Mehta, Carolyn S.P. Lam, Abhinav Goyal, Laurence S. Sperling, Nathan D. Wong, Niklas Hammar et al. · 2018 · Journal of Diabetes and its Complications
  59. Lipids as risk markers for type 2 diabetes
    Zachary T. Bloomgarden, ROBERT J. CHILTON · 2018 · Journal of Diabetes
  60. Treatment of Type 2 Diabetes by Patient Profile in the Clinical Practice of Endocrinology in Spain: Delphi Study Results from the Think Twice Program
    Carlos Morillas, Javier Escalada, Rafael Palomares, Diego Bellido, Fernando Gómez Peralta, Antonio Pérez · 2019 · Diabetes Therapy
  61. Diabetic Cardiomyopathy: Clinical and Metabolic Approach
    Dragan B. Djordjevic, Goran Pante Koracevic, Aleksandar Djordjević, Dragan B. Lović · 2020 · Current Vascular Pharmacology
  62. Metabolic Inflammation as a Common Thread in Cardio-Endocrine Diseases: Toward a Unified Therapeutic Framework
    Nidhi Patil, Neha Uppal, Simranjeet Bedi, Hiral Undhad, Pooja Joshi · 2026 · Cureus
  63. Risks of dementia and stroke in patients with hypertension using telmisartan or other renin‑angiotensin system inhibitors
    Chi‐Hung Liu, Ming‐Lung Tsai, Ning‐I Yang, Ting-Yu Chang, Tien‐Hsing Chen, Yi‐Chia Wei · 2026 · Alzheimer s & Dementia
  64. Inclisiran in patients with acute ischemic stroke: first data
    M. S. Cherepianskii, G. M. Ponomareva, Iaroslav B. Skiba, R. M. Abakarov, В В Дудайте, A. A. Cherepianskaia · 2023 · Kardiologiia
  65. Cost‐Utility Analysis of Low‐Dose Pioglitazone in a Population With Prediabetes and a History of Stroke or Transient Ischemic Attack
    Fei Yuan, John David Spence, Jean‐Éric Tarride · 2024 · Journal of the American Heart Association
  66. Glucose-lowering therapy in type 2 diabetes
    Gerit-Holger Schernthaner, Gerit-Holger Schernthaner · 2016 · Herz
  67. What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?
    Dragana Lovre, Wynn Htun, Carly Carrion, Vivian Andrew Fonseca · 2016 · Current Diabetes Reports
  68. Diabetes Update 2017
    Werner Alfons Scherbaum · 2017 · Der Diabetologe
  69. Glucose lowering strategies and cardiovascular disease in type 2 diabetes – teachings from the TOSCA.IT study
    Olga Vaccaro, Maria Masulli, Gabriele Riccardi · 2018 · Nutrition Metabolism and Cardiovascular Diseases
  70. A robust method to estimate regional polygenic correlation under misspecified linkage disequilibrium structure
    Guillaume Paré, Shihong Mao, Wei Q. Deng · 2018 · Genetic Epidemiology
  71. Dethroning the king?: The future of metformin as first line therapy in type 2 diabetes
    Silvio E. Inzucchi, Vivian Andrew Fonseca · 2019 · Journal of Diabetes and its Complications
  72. Escalating cost of oral and injectable antihyperglycemic drugs; are newer medications worth their price? A perspective from India and other developing countries
    Atul Luthra, Anoop Misra · 2020 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
  73. Prognosis After Stroke
    Víctor J. Del Brutto, Tatjana Rundek, Ralph L. Sacco · 2021 · Elsevier eBooks
  74. Romosozumab and cardiovascular safety—should we learn lessons from pioglitazone?
    Jubbin Jagan Jacob, Thomas Vizhalil Paul · 2022 · Osteoporosis International
  75. Diabetes: how to manage cardiovascular risk in secondary prevention patients
    Sarah L. Anderson, Joel C. Marrs · 2022 · Drugs in Context
  76. Recommendations for Early and Comprehensive Management of Type 2 Diabetes and Its Related Cardio-Renal Complications
    Ali K. Abu‐Alfa, Paola Atallah, Sami T. Azar, Elissar Dagher, Akram Salim Echtay, Mireille Amm, Habib G. Hazkial, Roland Kassab, R. Medlej, Malek A. Mohamad · 2022 · Diabetes Therapy
  77. Revealing rutaecarpine’s promise: A pathway to parkinson’s disease relief through PPAR modulation
    Yeying Wang, Bin Liao, Xuesong Shan, H. Ye, Yuqi Wen, Hua Guo, Feng Xiao, Hong Bo Zhu · 2025 · International Immunopharmacology
  78. Glycemic control and the heart: it matters how you get there
    Zachary T. Bloomgarden · 2016 · Journal of Diabetes
  79. Antihyperglycemic Medications and Impact on Cardiovascular Outcomes: A Review of Current Evidence
    Stormi E. Gale, Jeannie L. Poon, Kristin Watson · 2018 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  80. Pioglitazone and bladder cancer: improving research methods
    E. Ripamonti, Laurent Azoulay, Michał Abrahamowicz · 2020 · Diabetic Medicine
  81. Taking care of volunteers in a stroke trial: a new assisted-management strategy
    Amber Stuart, Jason Jonathon Sico, Catherine M. Viscoli, Ashis H. Tayal, Silvio E. Inzucchi, Gary A. Ford, Karen L. Furie, Robert Côté, John David Spence, David Tanné et al. · 2016 · Stroke and Vascular Neurology
  82. Neurological outcomes of antidiabetic therapy: What the neurologist should know
    Olaf Eberhardt, Helge Roland Topka · 2017 · Clinical Neurology and Neurosurgery
  83. Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins
    Abeer Anabtawi, Patrick M. Moriarty, John M. Miles · 2017 · Current Cardiology Reports
  84. The impact of glucose-lowering medications on cardiovascular disease
    Angelo Avogaro, Saula Vigili de Kreutzenberg, Gian Paolo Fadini · 2017 · Cardiovascular Endocrinology & Metabolism
  85. Type 2 Diabetes Mellitus. From the start – combination therapy
    Francesco Indovina, Pierpaolo Falcetta, Stefano Del Prato · 2018 · Diabetes Mellitus
  86. Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial
    Jeroen V. Koomen, Hiddo J.L. Heerspink, Ilse C. Schrieks et al. · 2019 · Diabetes Obesity and Metabolism
  87. Strategy and tactics of treatment of type 2 diabetes mellitus
    Milan Kvapil · 2019 · Vnitřní lékařství
  88. Type 2 diabetes mellitus and cardiovascular disease: focus on the effect of antihyperglycemic treatments on cardiovascular outcomes
    Ravi Choxi, Sumon Roy, Angeliki M. Stamatouli, Stephanie Mayer, Ion S. Jovin · 2020 · Expert Review of Cardiovascular Therapy
  89. Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus – Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft für Angiologie (DGA), der Deutschen Gesellschaft für Interventionelle Radiologie und minimal-invasive Therapie (DeGIR) sowie der Deutschen Gesellschaft für Gefäßchirurgie und Gefäßmedizin (DGG)
    Bernd M. Balletshofer, Dittmar Böckler, Holger Diener, Jörg Heckenkamp, Wulf D. Ito, Marcus Katoh, Holger Lawall, Nasser M. Malyar, Yves Oberländer, Peter Reimer et al. · 2021 · Diabetologie und Stoffwechsel
  90. The emergence of cardiodiabetology
    Paul D. Rosenblit, Norman E. Lepor, Nathan D. Wong · 2017 · Cardiovascular Endocrinology
  91. Clinical Approach to Assessment and Amelioration of Atherosclerotic Vascular Disease in Diabetes
    Ronald B Goldberg · 2020 · Frontiers in Cardiovascular Medicine
  92. Omega-3 fatty acid-rich fish oil supplementation prevents rosiglitazone-induced osteopenia in insulin resistant c57bl/6 mice and in vitro studies.
    Chiara Cugno, Dhanya Kizhakayil, Rita Calzone, Shaikh Mizanoor Rahman, Ganesh V. Halade, Md. Tanvir Rahman · 2020 · Research Square
  93. Glitazones and Glitazars
    Miles Fisher · 2022
  94. An explainable machine learning-based phenomapping strategy for adaptive predictive enrichment in randomized controlled trials
    Evangelos K. Oikonomou, Phyllis Thangaraj, Deepak L. Bhatt · 2023 · medRxiv
  95. Central vs site outcome adjudication in the IRIS trial
    Rachel Forman, Catherine M. Viscoli, Philip M. Bath · 2022 · Journal of Stroke and Cerebrovascular Diseases
  96. Association between PPAR γ polymorphisms and neurological functional disability of ischemic stroke
    Ran Yan, Xin Ye Qiu, Yalun Dai et al. · 2024 · Journal of Cerebral Blood Flow & Metabolism
  97. Impact of European Stroke Organisation secondary prevention guideline for ischaemic stroke / transient ischaemic attack
    Cameron Smith, Struan Wallis, Georgios Katsas, Ozzy Dincarslan, Jesse Dawson, Alan C. Cameron · 2024 · Journal of Stroke and Cerebrovascular Diseases
  98. The characteristic activity of regulatory B cells during the occurrence and development of insulin resistance
    Wei Lingling, Lijie Zhang, Dong Zhao, Yan Ma, Longyan Yang · 2024 · Endocrine
  99. Triglyceride–glucose index is a significant predictor of hospital mortality in non-diabetic critically ill patients with ischemic stroke: a retrospective cohort study of the MIMIC-IV database
    Ronghui Zhu, Qian He, Rui Wang, Yaoyong Tai, Chi Peng, Cheng Wu · 2025 · Acta Diabetologica
  100. Reprogramming macrophage metabolism for cardiovascular therapy: From molecular pathways to precision nanomedicine
    Huijun Guo, Yuji Xie, Yuxing Wang, Yuan Song, Tian Peng, Junmin Zhang, Jing Liu, Ying Xu, Wenqian Wu, Jing Wang et al. · 2026 · Materials Today Bio